HCPLive

Diabetes Dialogue wants to hear from you! We're planning a special "mailbag" episode for our post-ADA conference recap episode. Let us know your biggest, most pressing questions from the American Diabetes Association 84th Scientific Sessions in the comment below and our hosts, Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES and Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES, will answer them in our post-conference recap! Follow all our coverage of #ADA2024 using the link below: https://lnkd.in/ehpJJqS #Diabetes

Check out our 2024 first half recap for the field of #dermatology. We spotlight our 5 most popular dermatology approvals from the first 6 months of the year and highlight 3 upcoming decisions to watch for the second half of 2024! Check out our recap, which also includes a podcast episode with James Q. Del Rosso, DO, using the link below: https://lnkd.in/ePWY2cwT #FDANews

Our diabetes technology recap from #ADASciSessions is now live! In the preview, Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES break down how the data from SECURE-T2D reinforces their real-world experience with the Omnipod 5 (Insulet Corporation). For more, including highlights from Abbott, Sequel, and Medtronic, check out the full episode using the link below: https://lnkd.in/eEmPHr_6 #Diabetes #Type2Diabetes

The Fourth of July is upon us and while fireworks may bring joy to many, it can trigger veterans with #PTSD. In a recent interview, HCPLive spoke with Christopher Scuderi, DO, about effective strategies to manage PTSD symptoms triggered by fireworks and other loud noises. https://lnkd.in/eV5abrEw

Hear from Mitchell Shiffman, MD, as he discusses the current landscape of alcohol-associated #hepatitis treatment, unmet needs for these patients, and what larsucosterol may offer. Find the full interview here: https://lnkd.in/eHpyZBqN #Hepatology

Discover how different manifestations of plaque psoriasis influence treatment choice, and discuss when it may be appropriate for certain patients to transition to systemics. Watch Now bit.ly/40j11a6

Earlier today, Neurocrine Biosciences announced the FDA's acceptance of 2 New Drug Applications for crinecerfont in the treatment of children, adolescents, and adults with classic congenital adrenal hyperplasia. According to the company, the NDAs have received Priority Review designations and been assigned a PDUFA date in December 2024. https://lnkd.in/e4GFrPs5 #Endocrinology #FDANews

Sunday Spotlight: In a recent conversation, Payal Kohli, MD, FACC, shared her perspective on the rapidly changing landscape of cardiovascular risk management and how the community's definition of what is considered a "modifiable" risk factor has changed in recent years. https://lnkd.in/erQ89Bam #Cardiology #CardiovascularDisease

Article of the Week: At ADA 2024, data from the CATALYST trial suggests it could be time to retire the Ominous Octet in favor of the Noxious Nine, with data suggesting hypercortisolism was present in 24% of patients with difficult-to-control type 2 diabetes.

The 2024 Southern California Psychiatry Conference is the perfect educational opportunity for applying new strategies in psychiatric clinical practice. Save your spot now: https://bit.ly/3XEI96l #psych #socal